The authors reply

New England Journal of Medicine

Volumn 364, Issue 26, 2011, Pages 2557-2558

  Busse, William W ^a   Gergen, Peter J ^b   Calatroni, Agustin ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Rho Federal Systems Division Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN E; NITRIC OXIDE; OMALIZUMAB;

ALLERGIC ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; EOSINOPHIL COUNT; HOSPITALIZATION; HUMAN; LETTER; LOW DRUG DOSE; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIZATION; TREATMENT RESPONSE;

EID: 79959796818     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125:1378-86.
2. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8. (Pubitemid 40293345)
3. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma - full report 2007. Bethesda, MD: National Heart, Lung, and Blood Institute, August 28, 2007. (http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.htm.)